Author of

• 16637

  +

  P1.03 - Poster Session with Presenters Present (ID 455)

  • Event: WCLC 2016
  • Type: Poster Presenters Present
  • Track: Radiology/Staging/Screening
  • Presentations: 1
  • Moderators:
  • Coordinates: 12/05/2016, 14:30 - 15:45, Hall B (Poster Area)

  • 16683

    +

    P1.03-046 - Selection of Subjects at High-Risk for LDCT Lung Cancer Screening Using a Molecular Panel: Results by the ITALUNG Biomarker Study (ID 4279)

    14:30 - 14:30  |  Author(s): M. Peluso
    • Abstract

    Background:
    Low Dose Computer Tomography (LDCT) screening has been shown effective in reducing overall and lung cancer mortality, but there are still concerns for efficiency and the cost/harm benefit ratio.reduce costs. Subjects enrolled in trials evaluating LCDT as a test for the early detection of lung cancer represent the ideal population in which to study the possible use of molecular markers in a combined approach of screening.
    
    Methods:
    Out of 1406 subjects randomised in the intervention arm of the ITALUNG study and attending at baseline test, 1356 were enrolled, after specific consent, in the ITALUNG biomarker study. Screen detected lung cancers detected over the 4-years of screening (N=36 out of 38 in ITALUNG active arm) and 481 randomly selected subjects without lung cancer at end of the study follow up, were included in this analysis . DNA in plasma was quantified at baseline by Real Time PCR; microsatellite instability (MSI) and loss of heterozygosity (LOH) was assessed in blood and sputum. ITALUNG Biomarker Panel (IBP) was considered as positive if MSI /LOH and/or DNA Plasma values (cutoff 5 ng / ml) were positive.
    
    Results:
    The IBP results are shown in Table 1. Accuracy measure were estimated and showed high sensitivity for baseline screen-detected cases (94.4%) with a specificity of 60.0% (ROC Area:77%). Sensitivity and specificity were 66.7% and 60.1% for lung cancers screen detected at repeated LDCT (ROC Area: 63.4%). Figure 1
    
    
    
    Conclusion:
    The IBP showed good accuracy for the identification of screen detected baseline lung cancers, with a very high sensitivity and a specificity of about 60%. The analysis of IBP of the baseline sample showed low prediction at repeated test. IBP was confirmed as a potentially valid tool for baseline selection of high-risk subjects, saving about the 60% of the tests. Low predictive capacity of screen detected cases at repeated tests needs further investigation.